Our objective was to assess CD3 + /CD4 + T-cells and CD14 + monocytes at the gene expression level to predict response to MTX in order to personalize the treatment approach and ultimately improve outcomes in RA. This evidence concerns the gene CD4 and rheumatoid arthritis.